Back

Age-related amplification of inflammatory risk after percutaneous coronary Intervention: a 10-year large-sample prospective cohort study

31 August 2026 (11:01 - 11:09)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in older adults: ageing, risk stratification, and outcomes Cardiovascular Disease in the Elderly ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Menglu Liu

Beijing (China)

3 More presentations in this session

Presentation thumbnail
Comparative effectiveness of ticagrelor versus clopidogrel in older adults (≥75 years) with ST-segment elevation myocardial infarction: a target trial emulation study
Doctor R. Guo (Tianjin, CN)
Abstract
Presentation thumbnail
Lipoprotein(a) and cardiovascular disease in individuals aged 70-100 years
Doctor B. Nordestgaard (Copenhagen, DK)
Abstract
Presentation thumbnail
CVMI-age quantifies multidimensional cardiovascular aging and predicts cardiovascular events: a Chinese community-based cohort study
Doctor H. Xie (Beijing, CN)
Abstract

Access the full session

Session thumbnail
Cardiovascular disease in older adults: ageing, risk stratification, and outcomes

The Event

Event poster

ESC Congress 2026

31 August 2026 11:01 CET
You may be interested in
thumbnail
Congress Presentation
Analysis of the dynamics and prognostic significance of inflammatory markers in patients with heart failure who underwent acute coronary syndrome and percutaneous coronary intervention
29 June 2021
thumbnail
Congress Presentation
Low-density lipoprotein cholesterol, coronary plaque burden, and cardiovascular risk in individuals beyond 75 years of age
1 September 2025
thumbnail
Congress Presentation
Risk of myocardial infarction with coronary artery bypass grafting versus percutaneous coronary intervention: a systematic review and meta-analysis of fifteen randomised trials
2 September 2019
thumbnail
Congress Presentation
Impact of age and comorbidities on treatment delays in acute coronary syndrome: a retrospective analysis
20 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources